Celularity Inc. (NASDAQ:CELUW – Get Free Report) saw a large growth in short interest in the month of February. As of February 27th, there was short interest totaling 1,729 shares, a growth of 219.0% from the February 12th total of 542 shares. Based on an average daily trading volume, of 3,971 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily trading volume, of 3,971 shares, the days-to-cover ratio is currently 0.4 days.
Celularity Trading Up 17.6%
Shares of CELUW stock traded up $0.00 during trading hours on Friday, hitting $0.01. 5,600 shares of the company were exchanged, compared to its average volume of 18,934. The firm has a fifty day moving average of $0.01 and a 200 day moving average of $0.02. Celularity has a 1 year low of $0.01 and a 1 year high of $0.75.
About Celularity
Celularity, Inc is a clinical-stage biotechnology company headquartered in Florham Park, New Jersey, that specializes in the development and commercialization of allogeneic “off-the-shelf” cell therapies derived from postpartum placental cells. Leveraging a proprietary platform of placental- and umbilical-derived cells, the company seeks to deliver immune-modulatory, regenerative and anti-inflammatory treatments across oncology, immunology and other therapeutic areas. By harnessing the natural properties of placental cells, Celularity aims to overcome the limitations of autologous therapies and scale production to serve a broad patient population.
The company’s pipeline includes CYNK-001, an investigational natural killer (NK) cell therapy being evaluated for hematological malignancies and solid tumors, as well as other cell-based programs targeting viral infections and tissue repair.
Featured Articles
- Five stocks we like better than Celularity
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- Silver paying 20% dividend. Plus 68% share gains
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
